- Home
- OMER vs RIV Comparison
OMER vs RIV Comparison
Compare OMER & RIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OMER
- RIV
- Stock Information
- Founded
- OMER 1994
- RIV 2015
- Country
- OMER United States
- RIV United States
- Employees
- OMER N/A
- RIV N/A
- Industry
- OMER Biotechnology: Pharmaceutical Preparations
- RIV Finance Companies
- Sector
- OMER Health Care
- RIV Finance
- Exchange
- OMER Nasdaq
- RIV Nasdaq
- Market Cap
- OMER 274.3M
- RIV 260.6M
- IPO Year
- OMER 2009
- RIV N/A
- Fundamental
- Price
- OMER $4.48
- RIV $11.97
- Analyst Decision
- OMER Strong Buy
- RIV
- Analyst Count
- OMER 5
- RIV 0
- Target Price
- OMER $18.00
- RIV N/A
- AVG Volume (30 Days)
- OMER 933.6K
- RIV 87.6K
- Earning Date
- OMER 11-12-2025
- RIV 01-01-0001
- Dividend Yield
- OMER N/A
- RIV 12.85%
- EPS Growth
- OMER N/A
- RIV N/A
- EPS
- OMER N/A
- RIV N/A
- Revenue
- OMER N/A
- RIV N/A
- Revenue This Year
- OMER N/A
- RIV N/A
- Revenue Next Year
- OMER N/A
- RIV N/A
- P/E Ratio
- OMER N/A
- RIV N/A
- Revenue Growth
- OMER N/A
- RIV N/A
- 52 Week Low
- OMER $2.95
- RIV $9.63
- 52 Week High
- OMER $13.60
- RIV $12.43
- Technical
- Relative Strength Index (RSI)
- OMER 56.41
- RIV 38.85
- Support Level
- OMER $4.07
- RIV $11.92
- Resistance Level
- OMER $4.72
- RIV $12.03
- Average True Range (ATR)
- OMER 0.23
- RIV 0.08
- MACD
- OMER 0.02
- RIV 0.00
- Stochastic Oscillator
- OMER 61.19
- RIV 49.00
About OMER Omeros Corporation
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.
About RIV RiverNorth Opportunities Fund Inc.
Rivernorth Opportunities Fund Inc is a diversified, closed-end management investment company. The fund's investment objective is total return consisting of capital appreciation and current income.